Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline's (GSK) Promacta has won FDA approval as thrombocytopenia therapy in chronic hepatitis C patients.
Subscribe to our email newsletter
Promacta, brand name of eltrombopag in the US, will enable thrombocytopenia patients suffering from chronic hepatitis C to commence and sustain interferon-based therapy.
GlaxoSmithKline oncology president Paolo Paoletti said chronic hepatitis C is a significant public health issue.
"Some chronic hepatitis C patients suffer from low blood platelet counts. Commonly prescribed interferon-based therapies can worsen the problem of low blood platelet counts," Paoletti added.
"Today’s FDA approval of PROMACTA gives doctors a tool to address the low platelet challenge. This means more chronic hepatitis C patients may be able to start and stay on interferon-based therapy."
The US regulatory body considered data from Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE (ENABLE) 1 and 2 Phase III studies conducted in patients with platelet counts less than 75,000/µL.
Promacta when combined with interferon-based therapy was proven to establish a constant virologic response or viral cure.
Thrombocytopenia is a condition in which a patient’s blood contains a lower-than-normal number of platelets resulting in bleeding inside the body or beneath or from the skin.